Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over 9 years (2004-12)

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1582-1588

  Mendes, Rodrigo E ^a   Hogan, Patricia A ^b   Streit, Jennifer M ^a   Jones, Ronald N ^a,c   Flamm, Robert K ^a  

^a JMI LABORATORIES   (United States)

^b PFIZER INC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cfr; Oxazolidinones; Resistance; Surveillance

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; RNA 23S; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; CFR GENE; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENE MUTATION; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS; DRUG EFFECTS; GRAM POSITIVE COCCI; GRAM POSITIVE INFECTION; HEALTH; HEALTH SURVEY; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACETAMIDES; ANTI-INFECTIVE AGENTS; GLOBAL HEALTH; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; POPULATION SURVEILLANCE;

EID: 84902541725     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt541     Document Type: Article

References (26)

1. Whang DW, Miller LG, Partain NM et al. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 2013; 57: 5013-8.
2. Wunderink RG, Niederman MS, Kollef MH et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54: 621-9.
3. Michalska K, Karpiuk I, Krol M et al. Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem Lett 2013; 21: 577-91.
4. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011; 1241: 48-70.
5. Anda CD, Fang E, Das A et al. Integrated results from phase 3 studies comparing tedizolid 6 days vs. linezolid 10 days in patients with ABSSSI. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA, 2013. Abstract L-203, p. 46. American Society for Microbiology, Washington, DC, USA.
6. Jones RN, Kohno S, Ono Y et al. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 2009; 64: 191-201.
7. Jones RN, Ross JE, Fritsche TR et al. Oxazolidinone susceptibility patterns in 2004: report fromthe Zyvoxw Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006; 57: 279-87.
8. Ross JE, Fritsche TR, Sader HS et al. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvoxw Annual Appraisal of Potency and Spectrumstudy. Int J Antimicrob Agents 2007; 29: 295-301.
9. Ross JE, Jones RN, Hogan PA et al. Initial occurrences of linezolid (LZD) resistance (R) from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program (Europe, Latin America, Asia Pacific). In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2007. Abstract C2-865, p. 123. American Society for Microbiology, Washington, DC, USA.
10. Flamm RK, Farrell DJ, Mendes RE et al. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. J Chemother 2012; 24: 328-37.
11. Flamm RK, Mendes RE, Ross JE et al. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagn Microbiol Infect Dis 2013; 76: 206-13.
12. Biedenbach DJ, Farrell DJ, Mendes RE et al. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvoxw Annual Appraisal of Potency and Spectrum program. Diagn Microbiol Infect Dis 2010; 68: 459-67.
13. Ross JE, Utsuki U, Fumiaki I et al. Zyvoxw Annual Appraisal of Potency and Spectrum (ZAAPS) Program 2008 (Europe, Latin America, Canada, Asia Pacific): linezolid global in vitro susceptibility analyses. In: Abstracts of the One-hundred and ninth General Meeting-American Society for Microbiology, Philadelphia, PA, USA, 2009. Abstract A-078, p. 264. American Society for Microbiology, Washington, DC, USA.
14. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.
16. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters (Version 3.1). 2013. http://www.eucast.org/clinical_ breakpoints (12 December 2013, date last accessed).
17. Mendes RE, Deshpande LM, Kim J et al. Streptococcus sanguinis displaying a cross resistance phenotype to several ribosomal RNA targeting agents, including linezolid. In: Abstracts of the Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2012. Abstract C1-1343. American Society for Microbiology, Washington, DC, USA.
18. Mendes RE, Deshpande LM, Bonilla HF et al. Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio. Antimicrob Agents Chemother 2013; 57: 2923-8.
19. Mendes RE, Deshpande LM, Farrell DJ et al. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 2010; 65: 2329-35.
20. Toh SM, Xiong L, Arias CA et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Molec Microbiol 2007; 64: 1506-14.
21. Mendes RE, Deshpande L, Rodriguez-Noriega E et al. First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization. J Clin Microbiol 2010; 48: 3041-3.
22. Chen H, Wu W, Ni M et al. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms. Int J Antimicrob Agents 2013; 42: 317-21.
23. Sierra JM, Ortega M, Tarrago C et al. Decreased linezolid uptake in an in vitro-selected linezolid-resistant Staphylococcus epidermidis mutant. J Antimicrob Chemother 2009; 64: 990-2.
24. Floyd JL, Smith KP, Kumar SH et al. LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 5406-12.
25. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39: 1010-5.
26. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-9.